Last Price$8.511.2%
Market Cap$1,347.5M
9.2%
Peers median - 14.7%
(213.6%)
Peers median - (0.9%)
24.0%
Peers median - 8.2%
(375.6%)
Peers median - (11.1%)
Competing with OCUL
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$1,347.5M | 6.1 | $9.6 12.3% undervalued | (12.5%) | $63.7M | ($136.0M) | 9.2% | (213.6%) | 91.2% | (375.6%) | 24.0% | |
$124.8B | 5.7 | $187.5 61.6% overvalued | 17.8% | $11.0B | ($790.3M) | 11.5% | (7.2%) | 86.1% | (15.0%) | 10.7% | |
$77.0B | 6.3 | $1,048.3 46.0% undervalued | (25.4%) | $14.2B | $3,597.2M | 8.3% | 25.3% | 84.5% | 25.7% | 5.7% | |
$34.4B | 5.8 | $123.0 78.8% overvalued | 50.8% | $2,258.9M | ($211.2M) | 127.3% | (9.4%) | 86.8% | (41.3%) | N/A | |
$30.7B | 5.2 | $91.8 61.6% overvalued | 60.1% | $2,248.2M | ($42.6M) | 23.0% | (1.9%) | 85.6% | (7.2%) | 1,931.9% | |
$24.0B | 5.9 | $191.1 94.2% undervalued | 2.2% | €2,751.1M | (€229.8M) | (28.0%) | (8.4%) | 80.3% | (37.8%) | 1.3% | |
$14.5B | 5.4 | $71.6 120.5% undervalued | 11.2% | $2,263.9M | $2,769.0M | (3.8%) | 122.3% | 73.9% | 14.5% | 73.6% | |
$13.8B | 7.7 | $542.2 78.1% undervalued | 22.0% | $2,877.4M | $1,080.6M | 23.6% | 37.6% | 89.2% | 65.4% | 4.7% | |
$13.4B | 6.7 | $46.9 33.5% overvalued | (18.0%) | $2,850.5M | $475.4M | 17.8% | 16.7% | 78.6% | 11.0% | 10.7% | |
$13.3B | 5.9 | $0.6 96.9% overvalued | 330.2% | $0.0 | ($142.1M) | N/A | N/A | N/A | (3,335.4%) | 1.9% | |
$1,846.9M | 5.5 | $2,745.6 1,111.0% undervalued | 39.9% | $3,316.8M | ($1,041.0M) | 50.5% | (31.4%) | 83.7% | (43.2%) | 32.1% |
Compare OCUL Valuation Multiples with Peers
LTM
NTM
1Y Forward
2Y Forward
EV/Revenue
General
Valuation Multiple
Financial metrics
Company name
EV/Revenue
Revenue growth
EBITDA margin
Net Income margin
Ocular Therapeutix, Inc.OCUL
16.2x
9.0%
11.9%
(303.7%)
Median Peer Set
4.0x
14.8%
(19.3%)
7.5%
Alnylam Pharmaceuticals, Inc.ALNY
13.0x
23.0%
(38.6%)
(12.4%)
argenx SEARGX
N/A
198.6%
(60.5%)
(24.1%)
BeiGene, Ltd.BGNE
0.1x
73.7%
467.1%
(35.9%)
BioMarin Pharmaceutical Inc.BMRN
4.5x
18.0%
139.3%
15.0%
BioNTech SEBNTX
2.0x
(77.4%)
(89.7%)
24.4%
Regeneron Pharmaceuticals, Inc.REGN
4.3x
8.3%
10.4%
31.1%
Royalty Pharma plcRPRX
9.0x
(3.8%)
(43.7%)
37.9%
Summit Therapeutics Inc.SMMT
N/A
N/A
(68.7%)
N/A
United Therapeutics CorporationUTHR
3.8x
23.6%
25.7%
41.5%
Vertex Pharmaceuticals IncorporatedVRTX
10.9x
11.7%
N/A
(4.9%)
Compare OCUL Valuation Multiples Dynamics with Peers
Crunching data... Almost there!
FAQ
1. How does Ocular Therapeutix, Inc. (OCUL) revenue growth compare to peers and the industry?
Ocular Therapeutix, Inc. (OCUL) revenue growth is 9.2%, compared to the peers' median of 14.7%.
2. How does Ocular Therapeutix, Inc. (OCUL) Free Cash Flow (FCF) margin compare to peers and the industry?
Ocular Therapeutix, Inc. (OCUL) FCF margin is (213.6%), compared to the peers' median of (0.9%).
3. How does Ocular Therapeutix, Inc. (OCUL) Total Debt to Equity ratio compare to peers and the industry?
Ocular Therapeutix, Inc. (OCUL) Total Debt to Equity ratio is 24.0%, compared to the peers' median of 8.2%.
4. How does Ocular Therapeutix, Inc. (OCUL) ROIC (Return on Invested Capital) compare to peers and the industry?
Ocular Therapeutix, Inc. (OCUL) ROIC is (375.6%), compared to the peers' median of (11.1%).